Compare QSI & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QSI | PEPG |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.6M | 179.4M |
| IPO Year | 2020 | 2022 |
| Metric | QSI | PEPG |
|---|---|---|
| Price | $1.38 | $2.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $2.30 | ★ $10.19 |
| AVG Volume (30 Days) | ★ 9.3M | 936.2K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.17 | 25.61 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,436,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $406.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $1.31 |
| 52 Week High | $2.42 | $7.80 |
| Indicator | QSI | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 60.23 | 45.94 |
| Support Level | $0.81 | $2.24 |
| Resistance Level | $1.66 | $2.62 |
| Average True Range (ATR) | 0.17 | 0.23 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 59.23 | 32.20 |
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.